Renub

    United States Vaccine Market is forecasted to be more than US$ 11.4 Billion by the end of year 2026
    31 May, 2021

    According to the latest report by Renub Research, titled "United States Vaccine Market By Type (Influenza, Retrovirus, Hepatitis, Polio, DTap, HIB, Pneumococcal Conjugate, Varicella, MMR and HPV), Products and Pipeline, Companies" Vaccination is an easy, standard, secure, and practical way to protect people from dangerous diseases before they become infected. The vaccine works as a defensive tool in the body to increase the individual's resistance so that the immune system would get stronger. After taking the vaccine, the human immune system acts as an antibody, and if the person gets exposed, it hardly affects him or her. However, vaccines are made of killed or weakened forms of germs like viruses or bacteria, and it doesn't cause the disease and is evenly put at risk. According to Renub Research, United States Vaccine Market is poised to reach US$ 11.4 Billion by 2026.

     


    Vaccination policy in the United States comes under the U.S. health policy, which deals with immunization against infectious disease. Vaccination policy in the United States has been framed to eradicate the disease from the U.S. population. Vaccination policies affect various legal areas, including vaccine safety regulation, vaccine financing, vaccine mandates, adverse event reporting requirements, and compensation for injuries allegedly caused by vaccination. The United States Food and Drug Administration has the authority to enforce the safety of vaccines.


    According to the FDA, all new vaccines must first be tested in laboratory settings and on animals before being subjected to a series of increasingly rigorous tests in human subjects. Once vaccines are approved in the United States, the FDA regularly inspects their production facilities, tests their quality, and receives adverse reactions.


    The Advisory Committee on Immunization Practices gives scientific suggestions that are usually practiced by the central government, state governments, and health insurance companies, including vaccine schedule recommendations. Unless the child is placed at severe risk of harm, the American Academy of Pediatrics (AAP) advises doctors to respect parents' refusal to vaccinate their child after proper discussion.


    The National Vaccine Injury Compensation Program (VICP or NVICP) was created in 1986 due to the United States Congress passing the National Childhood Vaccine Injury Act (NCVIA) in response to a threat to vaccine supply caused by a DPT vaccine scare in the 1980s. This mentioned program covers all vaccines, including vaccines for diphtheria, tetanus, pertussis (whooping cough), measles, mumps, rubella (German measles), polio, hepatitis B, varicella (chickenpox), Haemophilus influenzae type b, rotavirus, and pneumonia.


    The COVID-19 vaccination campaign in the United States is an ongoing mass immunization campaign to combat the COVID-19 pandemic in the country. On December 10, 2020, the FDA approved the Pfizer–BioNTech COVID-19 vaccine, and mass vaccinations commenced on December 14, 2020. On December 17, 2020, the Moderna COVID-19 vaccine was approved for use, and on February 27, 2021, the Johnson & Johnson COVID-19 vaccine was approved.

     


    Vaccines have been distributed to states on a population-by-population basis, with vaccine rollouts carried out by each state in the United States. According to the Centers for Disease Control and Prevention, to save individuals from COVID-19 disease, a policy has been introduced for hospital and nursing home employees to be the first vaccinated to prevent infection.


    Vaccine Type - The Report Covers the Market, Administered Doses and Immunized Population of all the 10 diseases that were

    1. Influenza Vaccines
    2. Rotavirus
    3. DTaP
    4. HIB
    5. Hepatitis A & B
    6. Polio
    7. Varicella
    8. MMR
    9. Pneumococcal conjugate
    10. HPV


    All the company analysis has been covered from 4 Viewpoints that were Overview, Recent Developments, Revenue Analysis, Vaccinations Pipeline & Clinical Trials.

    Following Companies had been analyzed GlaxoSmithKline, plc, Merck & Co, Sanofi Pasteur, Pfizer, Inc.

    Related Reports